Business Context and Reporting Period
Company: Anixa Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2025
Reporting Period: Event-based report regarding a specific corporate development on the filing date.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a regulatory disclosure event.
Material Changes and Corporate Developments
- Clinical Trial Update: The Company and The Cleveland Clinic Foundation presented final data from the Phase 1 clinical trial of Anixa's investigational breast cancer vaccine.
- Event Details: The presentation was delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor of the vaccine technology.
- Disclosure Mechanism: The announcement was made via a press release (Exhibit 99.1) and a presentation abstract (Exhibit 99.2) under Item 7.01 (Regulation FD Disclosure).
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements regarding future events and results, identified by terms such as "believes," "expects," "intends," and "plans."
Risk Factors: Management cautions that actual results may differ materially from expectations due to risks and uncertainties, including those detailed in the Company's most recent Form 10-K and Form 10-Q filings. The Company explicitly states it has no obligation to update these statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific clinical data points and conclusions from the Phase 1 trial.
- Examine Exhibit 99.2 (Presentation Abstract) for detailed methodology and results presented by Dr. Justin Johnson.
- Consult the most recent Form 10-K and Form 10-Q for comprehensive risk factors and financial status, as this 8-K does not provide financial metrics.
- Verify the status of the investigational breast cancer vaccine and potential next steps for clinical development based on the final Phase 1 data.